Table 3.
Univariate and multivariate analysis of the associations between baseline clinical-, histopathological-, and molecular characteristics and the risk for a recurrence being invasive carcinoma compared to in situ carcinoma, among women with a primary DCIS and a known recurrence in the Uppsala/Västerås cohort, in the SweDCIS randomized study and in the two groups pooled together (n = 266).
| Risk of a recurrence after DCIS being invasive compared to a new in situ | ||||||
|---|---|---|---|---|---|---|
| U/V cohort (n = 100) | SweDCIS (n = 166) |
All DCIS with a recurrence (n = 266) |
||||
| Univariate* OR (95% CI) |
Multivariate†
OR (95% CI) |
Univariate* OR (95% CI) |
Multivariate†
OR (95% CI) |
Univariate* OR (95% CI) |
Multivariate†
OR (95% CI) |
|
| Mode of detection | ||||||
| Screening | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| Clinically | 1.82 (0.66–5.08) | 1.83 (0.61–5.5) | 1.64 (0.83–3.27) | 1.71 (0.85–3.46) | 1.72 (0.98–3.01) | 1.80 (1.02–3.19) |
| Tumor size | ||||||
| ≤15 mm | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| >15 mm or multifocal | 0.31 (0.12–0.84) | 0.32 (0.11–0.93) | 0.84 (0.41–1.63) | 0.84 (0.32–1.57) | 0.55 (0.33–0.93) | 0.54 (0.32–0.92) |
| Type of surgery | ||||||
| Breast conserving surgery | 1.0 | — | — | — | 1.0 | — |
| Mastectomy | 0.88 (0.20–3.88) | — | — | — | 1.13 (0.29–4.42) | — |
| Postoperative radiotherapy | ||||||
| No | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| Yes | 0.95 (0.39–2.34) | 1.27 (0.46–3.56) | 1.59 (0.80–3.20) | 1.70 (0.83–3.46) | 1.32 (0.76–2.27) | 1.41 (0.80–2.48) |
| Free margins | ||||||
| Yes | 1.54 (0.28–8.36) | — | 0.93 (0.41–2.13) | 1.24 (0.69–2.22) | — | |
| No or doubtful | 1.0 | — | 1.0 | 1.0 | — | |
| Nuclear grade | ||||||
| I | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| II | 1.37 (0.35–5.4) | 1.23 (0.29–5.15) | 0.21 (0.02–1.87) | 0.20 (0.02–1.81) | 0.75 (0.26–2.12) | 0.70 (0.25–2.02) |
| III | 1.58 (0.41–6.06) | 1.55 (0.38–6.37) | 0.12 (0.02–1.02) | 0.11 (0.01–0.96) | 0.53 (0.19–1.45) | 0.49 (0.18–1.35) |
| ER | ||||||
| Negative | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| Positive | 2.23 (0.86–5.78) | 2.29 (0.87–6.03) | 2.54 (0.91–7.10) | 3.34 (1.10–10.2) | 2.33 (1.17–4.65) | 2.52 (1.24–5.10) |
| PR | ||||||
| Negative | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| Positive | 1.03 (0.45–2.38) | 1.03 (0.44–2.39) | 1.83 (0.76–4.42) | 2.20 (0.83–5.40) | 1.32 (0.73–2.38) | 1.36 (0.75–2.47) |
| HER2 | ||||||
| Negative | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| Positive | 0.55 (0.23–1.30) | 0.60 (0.24–1.47) | 0.46 (0.19–1.11) | 0.42 (0.17–1.07) | 0.50 (0.27–0.92) | 0.48 (0.26–0.90) |
| EGFR | ||||||
| Negative | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| Positive | 0.35 (0.13–0.92) | 0.36 (0.13–0.98) | 0.62 (0.23–1.64) | 0.57 (0.21–1.58) | 0.45 (0.23–0.88) | 0.44 (0.22–0.88) |
| Ki67 | ||||||
| Low | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| High | 1.10 (0.41–2.97) | 1.09 (0.38–3.12) | 1.03 (0.38–2.82) | 1.10 (0.38–3.19) | 0.98 (0.50–1.94) | 0.93 (0.46–1.85) |
| Subgroups based on IHC | ||||||
| ER+/HER2− | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| ER+/HER2+ | 1.15 (0.35–3.77) | 1.27 (0.37–4.39) | 0.64 (0.21–2.02) | 0.64 (0.20–2.02) | 0.84 (0.37–1.89) | 0.83 (0.37–1.88) |
| ER−/HER2+ | 0.25 (0.07–0.93) | 0.26 (0.07–0.98) | 0.30 (0.08–1.12) | 0.22 (0.05–0.95) | 0.27 (0.11–0.68) | 0.24 (0.09–0.62) |
| **ER−/HER2−/CK5/6+ or EGFR+ |
0.42 (0.09–1.99) | 0.41 (0.08–0.98) | 0.75 (0.13–4.20) | 0.75 (0.13–4.30) | 0.54 (0.17–1.71) | 0.52 (0.16–1.65) |
| Unknown | 1.68 (0.46–6.17) | 1.62 (0.43–6.12) | 0.70 (0.33–1.48) | 0.70 (0.33–1.48) | 0.75 (0.42–1.34) | 0.76 (0.42– 1.35) |